Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

Telangana’s life sciences sector has recorded an impressive 23% growth in recent years, outpacing the national average of 14% ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

a life sciences company must have a good data ecosystem in place and a strong analytical process to pull ingenious insights from that data. In 2025, pharma companies must enable an instantaneous ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

About the author Nataliya Andreychuk is the CEO and co-founder of Viseven, a global MarTech services provider for life sciences and pharma industries. She is one of the top experts in digital ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...